Skip Navigation



Journal of Biochemistry Advance Access published online on March 3, 2008
Journal of Biochemistry, doi:10.1093/jb/mvn032
This Article
Right arrow Advance Access manuscript (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Liu, N.
Right arrow Articles by Zheng, D.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Liu, N.
Right arrow Articles by Zheng, D.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2008 The Japanese Biochemical Society

Erbin regulated sensitivity of MCF-7 breast cancer cells to TRAIL via ErbB2/AKT/NF-{kappa}B pathway

Ning Liu, Jindan Zhang, Jinchun Zhang, Shilian Liu, Yanxin Liu and Dexian Zheng*

National Laboratory of Medical Molecular Biology, Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences & Peking Union Medical College, 5 Dong Dan San Tiao, Beijing 100005, CHINA

*To whom correspondence s 'Erbin regulated sensitivity of MCF-7 to TRAIL via ErbB2 pathway' hould be addressed: Dexian Zheng, Institute of Basic Medical Sciences, 5 Dong Dan San Tiao, Beijing 100005, CHINA, Tel. 8610 6529 6409 Fax: 8610 6510 5102, E-mail: zhengdx{at}pumc.edu.cn or zhengdx{at}tom.com

Received December 28, 2007; Accepted February 19, 2008


  Abstract

We have reported that Erbin expression was down-regulated in the Jurkat leukemia T lymphocytes treated with the recombinant soluble tumor necrosis factor-related apoptosis-inducing ligand (rsTRAIL). Herein, we studied the expression and the regulation of Erbin and its binding partner, ErbB2, in the MCF-7 breast cancer cell line. We showed that the expressions of Erbin and ErbB2 were modulated by PKC{delta} inhibitor, rottlerin, in the TRAIL-resistant MCF-7 cell line. The affinity of Erbin-ErbB2 interaction was reduced by ErbB2 phosphorylation. Inhibiting the expression of Erbin facilitated the sensitivity of the MCF-7 cells to TRAIL via suppressing the ErbB2/AKT/NF-{kappa}B signaling pathway.

Key Words: Erbin, rsTRAIL, ErbB2, apoptosis, breast cancer


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.